Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

被引：0
|
作者：
Hanzel, J. [1 ]
Sever, N. [1 ]
Ferkolj, I. [1 ]
Stabuc, B. [1 ]
Smrekar, N. [1 ]
Kozelj, M. [1 ]
Novak, G. [1 ]
Gils, A. [2 ]
Drobne, D. [1 ]
机构：
[1] Univ Med Ctr Ljubljana, Dept Gastroenterol, Ljubljana, Slovenia
[2] Katholieke Univ Leuven, Lab Pharmaceut Biol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P603
引用
收藏
页码：S414 / S414
页数：1
相关论文
共 50 条
  • [1] VEDOLIZUMAB TROUGH LEVELS AT WEEK 6 PREDICT ENDOSCOPIC AND CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kozelj, Matic
    Novak, Gregor
    Gils, Ann
    Drobne, David
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S819 - S819
  • [2] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kurent, Tina
    Kozelj, Matic
    Novak, Gregor
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    Drobne, David
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749
  • [3] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [4] Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Di Mario, C.
    Papa, A.
    Gremese, E.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S398 - S398
  • [5] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [6] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [7] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S334 - S334
  • [8] Clinical utility of vedolizumab trough levels in the management of inflammatory bowel disease
    Maillard, Michel H.
    Jelk, Daniele
    Perreau, Matthieu
    Rossel, Jean-Benoit
    Pittet, Valerie
    Michetti, Pierre
    [J]. SWISS MEDICAL WEEKLY, 2018, 148 : 6S - 6S
  • [9] Vedolizumab Trough Levels in Inflammatory Bowel Disease: Initial Clinical Experience
    Badr, Al-Bawardy
    Guilherme, Piovezani Ramos
    Loftus, Edward, Jr.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S26 - S26
  • [10] Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
    Levartovsky, Asaf
    Cohen, Ido
    Abitbol, Chaya Mushka
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Kopylov, Uri
    Ben-Horin, Shomron
    Ungar, Bella
    [J]. BIOMEDICINES, 2023, 11 (06)
12345